Past-Year Pap Testing Rates Were Lower in 2022 Than 2019
By Elana Gotkine HealthDay Reporter
FRIDAY, June 14, 2024 -- Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study published in online June 14 in JAMA Network Open.
Tyrone F. Borders, Ph.D., and Amanda Thaxton Wiggins, Ph.D., from the University of Kentucky in Lexington, examined receipt of a Papanicolaou test in the past year among U.S. women overall and in those residing in rural and urban areas in 2019, 2020, and 2022. Data were obtained from the Health Information National Trends Survey; study participants were women aged 21 to 65 years.
Of the 188,243,531 women included in the analysis, 12.5 and 87.5 percent lived in rural and urban areas, respectively. The researchers found that unadjusted past-year Papanicolaou testing rates were significantly lower among rural versus urban residents in 2022 (48.6 versus 64.0 percent). Compared with 2019, in 2022 adjusted odds of past-year Papanicolaou testing were lower (odds ratio, 0.70).
"Health care organizations, especially those serving rural females, should consider, at least temporarily, expanding access to Papanicolaou tests to increase cervical cancer screening rates to prepandemic levels," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Survey Reveals Common Misconceptions About Human Papillomavirus
TUESDAY, March 11, 2025 -- The majority of people are unaware that the human papillomavirus (HPV) is more common among men and is associated with rising rates of cancers that...
Rural-Urban Disparities Seen in Cervical Cancer
FRIDAY, March 7, 2025 -- The incidence of and mortality from cervical cancer are higher among rural-residing women versus their urban counterparts within the United States...
2008 to 2022 Saw Declines in Cervical Precancers in Women Aged 20 to 24 Years
TUESDAY, March 4, 2025 -- From 2008 to 2022, there were considerable decreases in the rates of cervical intraepithelial neoplasia (CIN) grades 2 to 3 and adenocarcinoma in situ...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.